Updated hourlyHourly refreshFri, Oct 30, 2026
Press Release Database
Recent press releases, indexed by topic.
Finance · Healthcare
SAN FRANCISCO, Oct. 02, 2026 -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to six new employees to purchase an aggregate of 235,950 shares of the Company's common stock, effective as of October 1, 2026. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
Oct 2 · 20:30·GlobeNewswire
Finance
SAN DIEGO, Oct. 02, 2026 -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that on September 30, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of 90,775 restricted stock units (“RSUs”) and 32,725 non-qualified stock options (“NSOs”) to three newly hired non-executive employees. The foregoing inducement awards were granted as inducements material to the new employees entering into employment with Imagene in accordance with Nasdaq Listing Rule 5635(c)(4), and are subject to the terms and conditions of the Company’s 2025 Equity Inducement Plan and the applicable equity award agreements.
Oct 2 · 20:30·GlobeNewswire
Finance · Healthcare
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 02, 2026 -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on October 1, 2026 (the “Grant Date”), ORIC granted a total of 161,550 non-qualified stock options and 26,850 restricted stock units to six new non-executive employees who began their employment with ORIC in September 2026.
Oct 2 · 20:30·GlobeNewswire
Finance · Biotech & pharma
RADNOR, Pa., Oct. 02, 2026 -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, today announced that new data from the Launch-HTN trial of lorundrostat will be presented at the American Society of Nephrology Kidney Week 2026, taking place October 21-25 in Denver, Colorado.
Oct 2 · 20:30·GlobeNewswire
Finance · Aerospace & defense
Changes highlight the Company’s growth trajectory as a leading private, regional jet aviation business
Changes highlight the Company’s growth trajectory as a leading private, regional jet aviation business
Oct 2 · 20:30·GlobeNewswire
Finance · Healthcare
WALTHAM, Mass., Oct. 02, 2026 -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective October 1, 2026, the company granted non-qualified stock options to purchase an aggregate of 100,895 shares of its common stock to two new employees under Xilio Therapeutics’ Third Amended and Restated 2022 Inducement Stock Incentive Plan (the 2022 Inducement Stock Incentive Plan). Additionally, the company granted a non-qualified stock option to purchase 105,000 shares of its common stock under the 2022 Inducement Stock Incentive Plan to the company’s newly appointed Chief Medical Officer, Yariv Houvras, M.D., Ph.D.
Oct 2 · 20:30·GlobeNewswire
Finance
NEW YORK, Oct. 2, 2026 -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Gildan Activewear Inc. (NYSE: GIL) resulting from allegations that Gildan Activewear may have issued materially...
Oct 2 · 20:27·PR Newswire
Finance
NEW YORK, Oct. 02, 2026 --
WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Better Home & Finance Holding Company (NASDAQ: BETR) between March 13, 2026 and May 7, 2026, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 20, 2026.
Oct 2 · 20:26·GlobeNewswire
Finance
NEW YORK, Oct. 2, 2026 -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of The Ensign Group, Inc. (NASDAQ: ENSG) resulting from allegations that Ensign may have issued materially misleading...
Oct 2 · 20:22·PR Newswire
Finance
Strong demand leads to expanded funding, new rebate options DIAMOND BAR, Calif., Oct. 2, 2026 -- Following strong public demand and a successful launch, the South Coast Air Quality Management District (South Coast AQMD) Governing Board today approved $60.2 million in...
Oct 2 · 20:18·PR Newswire
Finance
NEW YORK, Oct. 2, 2026 -- Ares Management Corporation announced today that it has updated the time it will hold its earnings webcast/conference call for the third quarter ending September 30, 2026 to 9:00am ET on Thursday, October 29, 2026. Ares Management Corporation will...
Oct 2 · 20:15·PR Newswire
Finance
SALT LAKE CITY, Oct. 2, 2026 -- Extra Space Storage Inc. (the "Company") (NYSE: EXR) announced today it will release financial results for the three and nine months ended September 30, 2026, on Tuesday, October 27, 2026, after the market closes. The Company will host a...
Oct 2 · 20:15·PR Newswire